Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Amplyx brings in $67mm via Series C

Executive Summary

Antifungals developer Amplyx Pharmaceuticals Inc. raised $67mm in its Series C financing led by Sofinnova Venture Partners, which was joined by other first time backers Lundbeckfonden Ventures, Arix Bioscience, and Pappas Capital, and returning shareholders New Enterprise Associates, RiverVest Venture Partners, 3x5 RiverVest II, and BioMed Ventures. According to the Form D, 26 investors participated. A representative from Sofinnova and Lundbeckfonden will join the board. The company will use the proceeds for ongoing development of Phase I APX001, which is expected to enter Phase II for invasive aspergillosis and candidiasis later this year.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies